Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
actinium-225 PSMA
- Development stage
- Unknown
- Lead developer
- Affiliated Hospital of Southwest Medical University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
Actinium-225 PSMA (225Ac-PSMA) is a targeted alpha therapy (TAT) radiopharmaceutical platform designed for the treatment of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). It consists of a prostate-specific membrane antigen (PSMA)-targeting ligand (such as PSMA-617 or PSMA-I&T) conjugated to the alpha-emitting radioisotope actinium-225 (225Ac). Upon administration, the radioligand binds specifically to PSMA-expressing prostate cancer cells, where the actinium-225 decays, emitting high-energy alpha particles over a short range. This localized radiation induces double-stranded DNA breaks, leading to tumor cell death while minimizing damage to surrounding healthy tissues.
- Other names
- 225Ac-PSMA225Ac-PSMA RLT Agentactinium Ac 225 PSMAactinium-225-labeled PSMAactinium225-labeled PSMAactinium 225-labeled PSMAactinium-225-PSMAactinium225-PSMAactinium 225-PSMAactinium-225-PSMA radioligandactinium225-PSMA radioligandactinium 225-PSMA radioligand
02
Targets
DNAPSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on actinium-225 PSMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on actinium-225 PSMA.